Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

240 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines.
Shen X, Tang H, McDanal C, Wagh K, Fischer W, Theiler J, Yoon H, Li D, Haynes BF, Sanders KO, Gnanakaran S, Hengartner N, Pajon R, Smith G, Glenn GM, Korber B, Montefiori DC. Shen X, et al. Among authors: glenn gm. Cell Host Microbe. 2021 Apr 14;29(4):529-539.e3. doi: 10.1016/j.chom.2021.03.002. Epub 2021 Mar 5. Cell Host Microbe. 2021. PMID: 33705729 Free PMC article.
H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans.
Khurana S, Wu J, Verma N, Verma S, Raghunandan R, Manischewitz J, King LR, Kpamegan E, Pincus S, Smith G, Glenn G, Golding H. Khurana S, et al. J Virol. 2011 Nov;85(21):10945-54. doi: 10.1128/JVI.05406-11. Epub 2011 Aug 24. J Virol. 2011. PMID: 21865396 Free PMC article. Clinical Trial.
Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.
Smith GE, Flyer DC, Raghunandan R, Liu Y, Wei Z, Wu Y, Kpamegan E, Courbron D, Fries LF 3rd, Glenn GM. Smith GE, et al. Among authors: glenn gm. Vaccine. 2013 Sep 13;31(40):4305-13. doi: 10.1016/j.vaccine.2013.07.043. Epub 2013 Jul 26. Vaccine. 2013. PMID: 23891795 Free article.
A recombinant viruslike particle influenza A (H7N9) vaccine.
Fries LF, Smith GE, Glenn GM. Fries LF, et al. Among authors: glenn gm. N Engl J Med. 2013 Dec 26;369(26):2564-6. doi: 10.1056/NEJMc1313186. Epub 2013 Nov 13. N Engl J Med. 2013. PMID: 24224560 Free article. Clinical Trial. No abstract available.
An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization.
Raghunandan R, Lu H, Zhou B, Xabier MG, Massare MJ, Flyer DC, Fries LF, Smith GE, Glenn GM. Raghunandan R, et al. Among authors: glenn gm. Vaccine. 2014 Nov 12;32(48):6485-92. doi: 10.1016/j.vaccine.2014.09.030. Epub 2014 Sep 28. Vaccine. 2014. PMID: 25269094 Free PMC article.
240 results